Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)
To learn if the combination of enfortumab vedotin plus radiation therapy could help to control the disease.
Trial Details
- NCT ID
- NCT06434350
- Phase
- PHASE1 / PHASE2
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Cancer Type
- Bladder Cancer
- Interventions
- Enfortumab Vedotin
- Radiation Therapy
- Locations (sample)
- Houston, Texas, United States|29.76328,-95.36327
Key Eligibility Criteria
- Pathologically confirmed diagnosis of urothelial carcinoma of the bladder including patients with T4N0 and T1-4N2-3 disease. Participants with mixe…
- Be ≥ 18 years of age on the day of signing informed consent.
- ECOG performance status 0-2. NOTE: If participants is unable to walk due to paralysis, but is mobile in a wheelchair, participants is ambulatory fo…
- The participant has the following baseline laboratory data:
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Bladder Cancer Trials on Trialify →